Amino Acid Degrading Enzymes and Autophagy in Cancer Therapy

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Metabolic therapy, specifically amino acid deprivation using enzymes, is gaining traction for cancer treatment.
• Enzymes like L-asparaginase are FDA-approved, while others like arginase are in clinical trials for specific tumors.
• Drug resistance, often linked to autophagy, is a significant challenge in cancer therapy.

Purpose of the Study:

• To review recent advancements in enzyme-based amino acid deprivation for cancer therapy.
• To explore the role of autophagy in tumor metabolism under amino acid-deprived conditions.
• To highlight the potential of combining amino acid-degrading enzymes with autophagy modulators for enhanced cancer treatment.

Main Methods:

• Literature review of recent studies on amino acid-degrading enzymes in cancer.
• Analysis of the interplay between autophagy and tumor metabolism during amino acid deprivation.
• Discussion of preclinical findings on combination therapies.

Main Results:

• Several novel amino acid-degrading enzymes (glutaminase, methionase, etc.) are being developed for cancer treatment.
• Autophagy can be induced by amino acid deprivation, potentially fueling tumor metabolism.
• Preclinical studies suggest that manipulating autophagy alongside enzyme therapy is a promising strategy.

Conclusions:

• Amino acid-degrading enzymes represent a viable metabolic therapy for various cancers.
• Understanding and modulating autophagy is crucial for overcoming drug resistance in enzyme-based cancer therapies.
• Combination strategies involving amino acid-degrading enzymes and autophagy modulators hold significant therapeutic potential.